As advocates for the Cystic Fibrosis (CF) community, CF Europe is committed to facilitating the approval and equitable access to life-enhancing and life-saving therapies for all people living with CF in Europe. Today, we urge the European Medicines Agency (EMA) to extend the current license agreement of Kaftrio, which is proven to be safe and […]
Month: January 2025
CHOICES enrolment completed!
We are happy to announce that the enrolment of 40 participants within CHOICES has been successfully completed. CHOICES is the clinical trial of the HIT-CF project, and assesses the efficacy and safety of a new triple modulator therapy in people with CF with ultra-rare variants that were pre-selected using the innovative organoid test. You can […]